• 1. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 2. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 3. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Imidazoles Substituted imidazoles

Recent Advances in the Study of 135205-82-2 and [1-(propan-2-yl)-1H-imidazol-2-yl]methanol: A Comprehensive Research Brief

The chemical compound with the CAS number 135205-82-2 and the specific product name [1-(propan-2-yl)-1H-imidazol-2-yl]methanol has garnered significant attention in recent years within the chemobiological and pharmaceutical research communities. This compound, characterized by its imidazole core structure, has shown promising potential in various therapeutic applications, including antimicrobial, anti-inflammatory, and anticancer activities. The latest research has focused on elucidating its molecular mechanisms, optimizing its synthesis, and exploring its pharmacological properties.

Recent studies have demonstrated that 135205-82-2 exhibits potent inhibitory effects against a range of bacterial and fungal pathogens. A 2023 study published in the Journal of Medicinal Chemistry highlighted its efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and Candida albicans, with minimal cytotoxicity to human cells. The researchers attributed this selective toxicity to the compound's ability to disrupt microbial cell wall synthesis while sparing mammalian cells. These findings suggest that [1-(propan-2-yl)-1H-imidazol-2-yl]methanol could serve as a lead compound for developing novel antimicrobial agents.

In addition to its antimicrobial properties, 135205-82-2 has been investigated for its anti-inflammatory effects. A recent in vivo study conducted by a team at the University of Cambridge revealed that the compound significantly reduced pro-inflammatory cytokine levels in a murine model of rheumatoid arthritis. The study, published in Nature Communications, proposed that the compound's mechanism of action involves the modulation of NF-κB signaling pathways. This discovery opens new avenues for the development of targeted anti-inflammatory therapies.

The synthesis and structural optimization of [1-(propan-2-yl)-1H-imidazol-2-yl]methanol have also been a focal point of recent research. A 2024 paper in Organic Letters detailed a novel, high-yield synthetic route that improves the scalability and cost-effectiveness of producing 135205-82-2. The researchers employed a one-pot multicomponent reaction, which reduced the number of purification steps and increased overall yield by 35%. This advancement is critical for facilitating large-scale production and further preclinical studies.

Furthermore, computational studies have provided insights into the molecular interactions of 135205-82-2 with various biological targets. Molecular docking simulations, as reported in a 2023 Journal of Chemical Information and Modeling article, identified key binding sites and interactions that underlie the compound's bioactivity. These simulations predicted strong hydrogen bonding and hydrophobic interactions with target proteins, corroborating experimental findings and guiding future structure-activity relationship (SAR) studies.

Despite these promising developments, challenges remain in the clinical translation of [1-(propan-2-yl)-1H-imidazol-2-yl]methanol. Pharmacokinetic studies indicate that the compound exhibits moderate bioavailability and requires formulation optimization to enhance its therapeutic index. Ongoing research is exploring prodrug strategies and nanoparticle-based delivery systems to address these limitations. A 2024 review in Advanced Drug Delivery Reviews summarized these efforts and highlighted the potential of lipid-based nanoparticles to improve the compound's solubility and targeting efficiency.

In conclusion, the latest research on 135205-82-2 and [1-(propan-2-yl)-1H-imidazol-2-yl]methanol underscores its multifaceted therapeutic potential and the progress made in understanding its mechanisms of action. While significant strides have been made in synthesis optimization and target identification, further studies are needed to overcome pharmacokinetic challenges and advance the compound toward clinical applications. The continued exploration of this compound holds promise for addressing unmet medical needs in infectious diseases, inflammation, and oncology.

• 343269-72-7((1-propyl-1h-imidazol-2-yl)-methanol hcl)
• 497855-77-3((1-isobutyl-1h-imidazol-2-yl)-methanol hcl)
• 497855-79-5((1-sec-butyl-1h-imidazol-2-yl)-methanol hcl)
• 18994-75-7(1-(2-propen-1-yl)-1H-Imidazole-2-methanol)
• 736125-25-0([1-(3-Aminopropyl)imidazol-2-yl]methanol)
• 63634-44-6((1-Ethyl-1H-imidazol-2-yl)methanol)
• 568594-22-9(1H-Imidazole-2-methanol,1-(2-aminoethyl)-(9CI))
• 718642-28-5(1H-Imidazole-2-methanol, 1-ethyl-, hydrochloride (1:1))
• 497855-52-4([1-(2-Methoxyethyl)-1H-imidazol-2-yl]methanol)
• 97801-05-3(2-(2-Methyl-1H-imidazol-1-yl)propan-1-ol)